Secretory status of monoclonal immunoglobulin is related to the outcome of patients with myeloma: a retrospective study

The treatment of multiple myeloma (MM) with proteasome inhibitor (PI) bortezomib has significantly improved the survival of patients with MM. The 26S proteasome inhibitor targets the unfolded protein response (UPR) by inhibiting proteasome degradation of ubiquitinated paraprotein, subsequently leadi...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Blood Adv
Главные авторы: Qin, Xiao-Qi, An, Gang, Li, Zeng-Jun, Liu, Lan-Ting, Xu, Yan, Yang, Lin-Hua, Ma, Yan-Ping, Deng, Shu-Hui, Sui, Wei-Wei, Qin, Yu, Feng, Xiao-Yan, Zang, Mei-Rong, Yang, Wen-Juan, Zhang, Yan-Ru, Yi, Shu-Hua, Wang, Ting-Yu, Lv, Rui, Zou, De-Hui, Zhao, Yao-Zhong, Qiu, Lu-Gui
Формат: Artigo
Язык:Inglês
Опубликовано: American Society of Hematology 2019
Предметы:
Lymphoid Neoplasia
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC6418498/
https://ncbi.nlm.nih.gov/pubmed/30833275
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2018019851
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы